Clinical Trial Update: Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of ofatumumab and bendamustine in frontline and relapsed chronic lymphocytic leukemia; the study results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2013-12-16